Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3Other hematologic neoplasm 2Plasma cell 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 561Leukemia 282Precursor Cell Lymphoblastic Leukemia-Lymphoma 235Lymphoma 160Myelodysplastic Syndromes 111Burkitt Lymphoma 91Congenital Abnormalities 86Lymphoma, Non-Hodgkin 85Leukemia, Monocytic, Acute 84Leukemia, Myelomonocytic, Acute 82Lymphoma, Large B-Cell, Diffuse 80Leukemia, Erythroblastic, Acute 75Leukemia, Megakaryoblastic, Acute 72Recurrence 70Lymphoma, Mantle-Cell 70Lymphoma, Follicular 49Hodgkin Disease 44Leukemia, Myelomonocytic, Chronic 43Leukemia, Biphenotypic, Acute 43Lymphoma, Large-Cell, Immunoblastic 37Blast Crisis 37Anemia, Refractory, with Excess of Blasts 36Leukemia, Myelogenous, Chronic, BCR-ABL Positive 35Leukemia, Lymphocytic, Chronic, B-Cell 33Myeloproliferative Disorders 30Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 28Lymphoma, B-Cell, Marginal Zone 24Leukemia, Myeloid, Chronic-Phase 23Leukemia, Eosinophilic, Acute 23Leukemia, Basophilic, Acute 22

Interventions

Cyclophosphamide 8fludarabine phosphate 7tagraxofusp 6venetoclax 5fludarabine 5Whole-Body Irradiation 4Mycophenolic Acid 4Methotrexate 4Thiotepa 3Dexamethasone 3Cytarabine 3Cyclosporine 3Calcium Dobesilate 3merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Vincristine 2Tacrolimus 2Specimen Handling 2Rituximab 2Peripheral Blood Stem Cell Transplantation 2Cyclosporins 2Azacitidine 2relmapirazin 1prednylidene 1lorvotuzumab mertansine 1exifone 1deltacortene 1azathiopurine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Blastic Plasmacytoid Dendritic Cell Neoplasm × Cytarabine × Clear all
NCT04216524 2026-04-14

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Myeloid

Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT06325748 2026-02-12

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Senti Biosciences

Phase 1 Active not recruiting
21 enrolled
MyeloidOther hematologic neoplasmPlasma cell

Blastic Plasmacytoid Dendritic Cell Neoplasm, Multiple Myeloma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT05476770 2024-12-06

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Therapeutic Advances in Childhood Leukemia Consortium

Phase 1 Recruiting
54 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Hodgkin Disease, Leukemia, Biphenotypic, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡